Why Treatment Shifts From Surgery to — Immunotherapy

Surgery works well when cancer is contained to one visible area with a margin your surgeon can safely remove. Once it has spread to distant organs or lymph nodes, there are likely cancer cells circulating in the body, some too small to see on any scan. Cutting out one new tumour would not reach cells settling elsewhere. This is why your team shifts to a systemic treatment such as immunotherapy, which travels through the bloodstream and can act on cancer wherever it has moved, rather than relying on surgery to reach every site one by one.

No. You will usually still have regular scans to see how the cancer is responding to immunotherapy, and your surgeon may stay involved if a spot needs to be removed, biopsied, or watched closely. Surgery and immunotherapy are not either-or once cancer has spread — your tumour board often uses both, with immunotherapy as the main body-wide treatment and surgery handling specific local problems. Your care team will tell you which specialists you still need to see and how often, based on how the disease is behaving.

Stage describes how far the cancer has spread, and it is one of the main things a tumour board looks at when choosing treatment, but it is not the only factor. Two patients with a similar stage can still be offered different plans depending on exactly where the cancer has reached, whether it can realistically all be removed, and their overall health. Ask your team to explain how your specific findings led to their recommendation, rather than assuming stage alone decided it.

You can always share your concerns with your tumour board, but the choice is guided by what can actually control the cancer, not preference alone. If disease has spread beyond what surgery can reach, surgery alone is unlikely to control it, even though it avoids immunotherapy's side effects. Your team can explain what support is available for managing immune-related side effects, and whether an adjusted systemic approach might suit you better than stopping systemic treatment altogether.

Yes, this happens for some patients. If immunotherapy controls the disease well and only a few spots remain active, your tumour board may then consider removing or treating those specific areas with surgery or radiation, while continuing or adjusting systemic treatment. This is decided case by case, based on scans and how stable the response looks over time. It does not mean the cancer is fully gone, so your team will still recommend ongoing monitoring.

No. Whether a cancer spreads beyond what surgery can reach depends on the biology of that specific cancer, not on anything you did or did not do. Melanoma and other skin cancers can travel through the blood or lymph system before it is visible on any scan, even after successful earlier surgery. Needing immunotherapy now is a sign of how the disease is behaving, not a sign that treatment failed because of a mistake. Your team can talk through what led to this point if that would help you.